Even though HER2 is emerging as a promising target for advanced NSCLC, its role has not yet been confirmed. Thus, ESMO recommends that patients with metastatic HER2-mutated NSCLC should be enrolled in a clinical trial. Recruiting trials of targeted therapy for HER2-mutated NSCLC include DESTINY-Lung02 and a phase 2 trial of ado-trastuzumab emtansine for patients with HER2 amplified or mutant cancers. Search for additional clinical trials here. ESMO guidelines can be accessed here.
Learn more about targeting HER2 in NSCLC.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Maurie Markman. Fast Five Quiz: ERBB2 (HER2) Mutation in Non-Small Cell Lung Cancer - Medscape - Nov 23, 2021.